Please enable Javascript
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
mocravimod
FDA Grants Fast Track Designation for Mocravimod in Combination with HSCT for AML
Leah Sherwood
Acute Myeloid Leukemia
|
November 14, 2022
Mocravimod is a synthetic, sphingosine 1-phosphate receptor modulator that has been assessed in phase I and II trials.
Read More
S1PR Modulator Mocravimod Granted Fast Track Designation
Leah Lawrence
Acute Myeloid Leukemia
|
February 2, 2023
Mocravimod is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator.
Read More
Advertisement
Advertisement
Advertisement
Advertisement